AcelRx Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume794,372 shs
Average Volume3.88 million shs
Market Capitalization$142.92 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AcelRx Pharmaceuticals logo

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.09 out of 5 stars

Medical Sector

1241st out of 2,214 stocks

Pharmaceutical Preparations Industry

583rd out of 869 stocks

Analyst Opinion: 0.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

Is AcelRx Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AcelRx Pharmaceuticals stock.
View analyst ratings for AcelRx Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than AcelRx Pharmaceuticals?

Wall Street analysts have given AcelRx Pharmaceuticals a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AcelRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 10,830,000 shares, a decline of 31.2% from the June 15th total of 15,740,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is currently 5.9 days. Currently, 9.3% of the company's shares are short sold.
View AcelRx Pharmaceuticals' Short Interest

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for AcelRx Pharmaceuticals

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Sunday, May, 16th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The specialty pharmaceutical company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.53 million.
View AcelRx Pharmaceuticals' earnings history

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRX stock has decreased by 1.6% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACRX?

1 equities research analysts have issued 12-month target prices for AcelRx Pharmaceuticals' stock. Their forecasts range from $0.84 to $0.84. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $0.84 in the next year. This suggests that the stock has a possible downside of 30.0%.
View analysts' price targets for AcelRx Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 53, Pay $932.47k)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 58, Pay $675.76k)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 52, Pay $604.36k)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 58, Pay $478.09k)
  • Mr. Lawrence G. Hamel, Consultant (Age 69)

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Kovack Advisors Inc. (0.03%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends for AcelRx Pharmaceuticals

Which major investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including Kovack Advisors Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Adrian Adams, Mark G Edwards, and Vincent J Angotti.
View insider buying and selling activity for AcelRx Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.20.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals has a market capitalization of $142.92 million and generates $5.42 million in revenue each year. The specialty pharmaceutical company earns $-40,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does AcelRx Pharmaceuticals have?

AcelRx Pharmaceuticals employs 54 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is

Where are AcelRx Pharmaceuticals' headquarters?

AcelRx Pharmaceuticals is headquartered at 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.